Literature DB >> 2822900

Actions of mu, delta and kappa opioid agonists and antagonists on mouse primary afferent neurons in culture.

M A Werz1, D S Grega, R L MacDonald.   

Abstract

The effects of selective mu, delta and kappa opioid agonists and antagonists were studied on somatic calcium-dependent action potentials recorded from mouse dorsal root ganglion (DRG) neurons grown in dissociated cell culture. The mu selective agonist, PL 017, and the delta selective agonist, [D-Pen2, L-Pen5] enkephalin (DPLPE), reduced action potential duration of a subpopulation (21/56) of DRG neurons. Leucine-enkephalin reduced action potential duration of all neurons sensitive to PL 017 or DPLPE, whereas 85% of neurons responding to leucine-enkephalin responded to either PL 017 or DPLPE. Only 15% of neurons responded to both PL 017 and DPLPE. There was no significant difference in the response to PL 017 or DPLPE when compared to leucine-enkephalin. In another experiment, the kappa selective agonist dynorphin A (DYN A), PL 017 and DPLPE reduced action potential duration of a subpopulation (15/67) of DRG neurons. There was a heterogeneous response among neurons to PL 017, DPLPE and DYN A inasmuch as 21.4% of neurons responded to all three agonists, 35.7% responded to PL 017 and DYN A, 35.7% responded only to PL 017 and 7.1% responded only to DYN A. Responses to the mu selective agonist PL 017 were antagonized by the reversible opioid antagonist naloxone and the selective mu antagonist SMS 201-995 in a concentration-dependent fashion. Responses to PL 017 were not altered by the selective delta antagonist ICI 174864. Responses to PL 017 were reduced by the irreversible, selective mu antagonists beta-funaltrexamine and naloxonazine in a concentration-dependent fashion.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2822900

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  8 in total

1.  Teleantagonism: A pharmacodynamic property of the primary nociceptive neuron.

Authors:  Mani I Funez; Luiz F Ferrari; Djane B Duarte; Daniela Sachs; Fernando Q Cunha; Berenice B Lorenzetti; Carlos A Parada; Sérgio H Ferreira
Journal:  Proc Natl Acad Sci U S A       Date:  2008-09-17       Impact factor: 11.205

2.  Sufentanil, morphine, met-enkephalin, and kappa-agonist (U-50,488H) inhibit substance P release from primary sensory neurons: a model for presynaptic spinal opioid actions.

Authors:  H M Chang; C B Berde; G G Holz; G F Steward; R M Kream
Journal:  Anesthesiology       Date:  1989-04       Impact factor: 7.892

Review 3.  Ethanol and opioid receptor signalling.

Authors:  M E Charness
Journal:  Experientia       Date:  1989-05-15

4.  Delta-opioid mediated inhibitions of acute and prolonged noxious-evoked responses in rat dorsal horn neurones.

Authors:  A F Sullivan; A H Dickenson; B P Roques
Journal:  Br J Pharmacol       Date:  1989-11       Impact factor: 8.739

5.  Axotomy reduces the effect of analgesic opioids yet increases the effect of nociceptin on dorsal root ganglion neurons.

Authors:  F A Abdulla; P A Smith
Journal:  J Neurosci       Date:  1998-12-01       Impact factor: 6.167

6.  Presynaptic opioid receptors on dopaminergic nerves in the rabbit caudate nucleus: coupling to pertussis toxin-sensitive G-proteins and interaction with D2 autoreceptors?

Authors:  R Jackisch; H Hotz; C Allgaier; G Hertting
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-03       Impact factor: 3.000

7.  Opioid receptor-mediated inhibition of 3H-dopamine and 14C-acetylcholine release from rat nucleus accumbens slices. A study on the possible involvement of K+ channels and adenylate cyclase.

Authors:  M H Heijna; F Hogenboom; A H Mulder; A N Schoffelmeer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-06       Impact factor: 3.000

8.  Distribution of functional opioid receptors in human dorsal root ganglion neurons.

Authors:  Jamie K Moy; Jane E Hartung; Melissa G Duque; Rob Friedman; Vidhya Nagarajan; Emanuel Loeza-Alcocer; H Richard Koerber; Thomas Christoph; Wolfgang Schröder; Michael S Gold
Journal:  Pain       Date:  2020-07       Impact factor: 7.926

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.